Testing a lab platform that analyzes samples from people with blood cancers
Tests whether multi-omics analyses of patient samples are feasible in blood cancers.
Plain-language title generated from the registry record
Registry title: Feasibility of a Multi-omics Platform for Hematological Malignancies
Key facts
- Where
- Parma, ItalySee the site
Where in Italy
- University of ParmaParma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda Ospedaliero-Universitaria di Parma
- Trial code
- NCT07445438
- Record updated
- 3 March 2026
- Original description
This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.Read full original descriptionShow less
Feasibility of a Multi-omics Platform for Hematological Malignancies
This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.
Inclusion: Patient aged > 2 year old; Retrospective study:; Patients previously diagnosed with hematological malignancies; Prospective study:; Patients with clinical suspect of hematological malignancies requiring a diagnostic assessment using BM or PB samples, biopsies of lymph nodes or tissues with metastatic involvement, or other biological fluids (such as CSF, pathologic pleural effusion); Patients with clinical suspicion of R/R onco-hematological disorder, requiring a diagnostic assessment using BM aspirate/biopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from lumbar puncture, tissue aspirate etc; Patients with blastic transformation from a chronic condition or suspect of R/R hematological disease requiring a diagnostic assessment using PB drawn, BM aspirate/biopsy, lymph nodes biopsies, or biopsies of tissues with metastatic involvement, including CSF from lumbar puncture, tissue aspirate, etc.
Exclusion: Patient without a diagnosis of hematological malignancy; Age <2 year old.